Nonserious Infections Should There Be Cause for Serious Concerns?

被引：14

作者：

Dao, Kathryn H. ^{[1
]}

Herbert, Morley ^{[2
]}

Habal, Nadia ^{[3
]}

Cush, John J. ^{[1
]}

机构：

[1] Baylor Res Inst, Dallas, TX 75229 USA

[2] Med City Dallas Hosp, Dallas, TX 75230 USA

[3] No Virginia Arthrit, Alexandria, VA 22304 USA

来源：

RHEUMATIC DISEASE CLINICS OF NORTH AMERICA | 2012年 / 38卷 / 04期

关键词：

Nonserious infections; Anti-TNF; Adalimumab; Etanercept; Infliximab; Safety; Rheumatoid arthritis; ANTITUMOR NECROSIS FACTOR; PLACEBO-CONTROLLED TRIAL; ALPHA MONOCLONAL-ANTIBODY; PHASE-III TRIAL; RECEIVING CONCOMITANT METHOTREXATE; ACTIVE RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; PSORIATIC-ARTHRITIS; ANKYLOSING-SPONDYLITIS; 50; MG;

D O I：

10.1016/j.rdc.2012.08.016

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Nonserious infections (NSIE) as colds, flu syndromes, and urinary tract infection, are the most common infections seen in patients with immune mediated inflammatory diseases. Yet, little is known about the impact of immunosuppression, particularly with tumor necrosis factor inhibitors (TNFi), on these infections. A systemic review of large, randomized controlled trials was conducted to identify incidence, types, and outcomes of NSIE associated with the most commonly prescribed TNFi: adalimumab, etanercept, and infliximab.

引用

页码：707 / +

页数：20

共 61 条

[1]

Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis - Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) [J].

Antoni, CE ;

Kavanagh, A ;

Kirkham, B ;

Tutuncu, Z ;

Burmester, GR ;

Schneider, U ;

Furst, DE ;

Molitor, J ;

Keystone, E ;

Gladman, D ;

Manger, B ;

Wassenberg, S ;

Weier, R ;

Wallace, DJ ;

Weisman, MH ;

Kalden, JR ;

Smolen, J .

ARTHRITIS AND RHEUMATISM, 2005, 52 (04) :1227-1236

[2]

Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists [J].

Askling, Johan ;

Fored, C. Michael ;

Brandt, Lena ;

Baecklund, Eva ;

Bertilsson, Lennart ;

Feltelius, Nils ;

Coster, Lars ;

Geborek, Pierre ;

Jacobsson, Lennart T. ;

Lindblad, Staffan ;

Lysholm, Jorgen ;

Rantapaa-Dahlqvist, Solbritt ;

Saxne, Tore ;

van Vollenhoven, Ronald F. ;

Klareskog, Lars .

ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (10) :1339-1344

[3]

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [J].

Bathon, JM ;

Martin, RW ;

Fleischmann, RM ;

Tesser, JR ;

Schiff, MH ;

Keystone, EC ;

Genovese, MC ;

Wasko, MC ;

Moreland, LW ;

Weaver, AL ;

Markenson, J ;

Finck, BK .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) :1586-1593

[4]

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials [J].

Bongartz, T ;

Sutton, AJ ;

Sweeting, MJ ;

Buchan, I ;

Matteson, EL ;

Montori, V .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (19) :2275-2285

[5]

The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment [J].

Breedveld, FC ;

Weisman, MH ;

Kavanaugh, AF ;

Cohen, SB ;

Pavelka, K ;

van Vollenhoven, R ;

Sharp, J ;

Perez, JL ;

Spencer-Green, GT .

ARTHRITIS AND RHEUMATISM, 2006, 54 (01) :26-37

[6]

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis - A randomized, controlled trial [J].

Clair, EWS ;

van der Heijde, DMFM ;

Smolen, JS ;

Maini, RN ;

Bathon, JM ;

Emery, P ;

Keystone, E ;

Schiff, M ;

Kalden, JR ;

Wang, B ;

DeWoody, K ;

Weiss, R ;

Baker, D .

ARTHRITIS AND RHEUMATISM, 2004, 50 (11) :3432-3443

[7]

Recombinant human tumor necrosis factor receptor, (etanercept) for treating ankylosing spondylitis - A randomized, controlled trial [J].

Davis, JC ;

van der Heijde, D ;

Braun, J ;

Dougados, M ;

Cush, J ;

Clegg, DO ;

Kivitz, A ;

Fleischmann, R ;

Inman, R ;

Tsuji, W .

ARTHRITIS AND RHEUMATISM, 2003, 48 (11) :3230-3236

[8]

Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy - Results from the British Society for Rheumatology Biologics Register [J].

Dixon, W. G. ;

Watson, K. ;

Lunt, M. ;

Hyrich, K. L. ;

Silman, A. J. ;

Symmons, D. P. M. .

ARTHRITIS AND RHEUMATISM, 2006, 54 (08) :2368-2376

[9]

The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study [J].

Dixon, W. G. ;

Kezouh, A. ;

Bernatsky, S. ;

Suissa, S. .

ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (06) :956-960

[10]

Frequency of infection in patients with rheumatoid arthritis compared with controls - A population-based study [J].

Doran, MF ;

Crowson, CS ;

Pond, GR ;

O'Fallon, WM ;

Gabriel, SE .

ARTHRITIS AND RHEUMATISM, 2002, 46 (09) :2287-2293

← 1 2 3 4 5 6 7 →